88 results
To demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells in addition to state of the art treatment is safe and reduces allcause mortality in patients with reduced left ventricular ejection fraction (…
Primary Objective:The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and MTD/MAD/alternate dose of BMS-986156 administered alone and in combination with nivolumab in subjects with advanced solid tumors.…
The primary objective is to determine whether adjuvant treatment with natural dendritic cell (nDC) vaccination, after complete radical lymph node dissection or sentinel node procedure in stage IIIB and IIIC melanoma patients, improves recurrence-…
To evaluate the efficacy of a single intra-articular injection of ASC in mild to moderate knee OA (KL 2-3) based on improvement of WOMAC pain and function subscore at 6 month, compared to placebo (vehic: 0.5% glucose in saline with 4.5% alb).The…
Primary Objective* To determine the OS of subjects treated with ICT-107 and standard of care (RT and TMZ) vs. placebo control and standard of care (RT and TMZ) :Secondary Objectives* To determine the OS of subjects with unmethylated MGMT tumors…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
To determine the efficacy and safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of early stage non-traumatic osteonecrosis of the femoral head.
Objectives: 1. The primary objective is to evaluate the safety and immune modulation of TIL plus IFN* in epithelial ovarian cancer (EOC) patients and to determine the optimal dose of IFN* that can be given in combination with chemotherapy.2.…
To assess whether (neo)-adjuvant DCT in combination with eP/D is feasible in early stage epithelioid MPM patients after first-line chemotherapy.
The main objective of this study is to test the hypothesis that SVF alleviates pain and increases maximal interincisal mouth opening in patients with TMJ osteoarthritis.
Primary: To evaluate the safety and toxicity of TIL therapy in patients with metastatic NSCLC preceded by chemotherapy with or without immunotherapy.Secondary: Clinical response according to RECIST 1.1 criteria and immune response criteria (irRC).…
Primary Objective:To evaluate the efficacy of LN-145 measured by objective response rate (ORR) usingResponse Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by theIndependent Review Committee (IRC) for Cohorts 1 and 2 and by the…
The primary objective of this study are 1) to evaluate the safety and determine the highest tolerable dose of NEO-PTC-01 in patients withunresectable or metastatic melanoma. 2) to evaluate the safety of NEO-PTC-01 in combination with a fixed dose of…
The aim of this research is to investigate whether it is feasible and safe to treat operated pancreatic cancer patients who have completed standard of care treatment with dendritic cell immunotherapy using dendritic cells loaded with autologous…
The objective of this prospective, randomized study is to investigate the efficacy and safety of HSCT compared to the comparator group (alemtuzumab, cladribine or ocrelizumab) in patients with aggressive relapsing remitting MS. In Norway, the…
To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic disease after (modified) FOLFIRINOX.
In this randomized controlled phase III study we will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression free survival when randomly compared…
Cohort 1 - LN-145 monotherapy in patients who have progressed during or following systemic therapy for recurrent, metastatic, or persistent disease and Cohort 2 - LN-145 monotherapy in patients previously treated with an antiprogrammedcell death…
The primary objective of this study is to show immunological efficacy of autologous tumor-lysate loaded XP-DC in epithelial ovarian cancerpatients undergoing (neo-)adjuvant chemotherapy. The secondary objectives are the safety and feasibility of…
To confirm the efficacy and safety of a single intra-arterial administration of REX-001 to treat ischemic ulcers in subjects with CLTI Rutherford Category 5 and DM.